12:45 PM EDT, 05/02/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target to $182 from $277, 12.8x our FY 25 (Sep.) EPS, a discount to historical due to tariffs and research funding cuts. We trim our FY 25 EPS by $0.15 to $14.22 and FY 26 by $0.10 to $15.51. FQ2 EPS of $3.35 vs. $3.17, beat consensus by $0.07. BD Medical was the standout performer with 12.7% Y/Y top-line growth, with solid organic growth bolstered by the acquisition of APM. This was partially offset by declines in the Life Sciences and Interventional segments, which faced headwinds from lower research funding. BDX forecasts a tariff impact of $0.25 for FY 25, bringing EPS guidance to a range of $14.06-$14.34 versus a $14.30-$14.60 previously. BDX announced a $2.5B investment in U.S. manufacturing capacity over the next five years, which we think reflects a longer-term view that tariffs will remain and/or resurface. Our revised opinion reflects that changes in government policy, including cuts to U.S. research grants, will negatively impact research instrument sales going forward.